Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging

• Published in: British journal of radiology Vol. 88; no. 1053; p. 20150163
• Main Authors: Jeon, T Y, Kim, C K, Kim, J-H, Im, G H, Park, B K, Lee, J H
• Format: Journal Article
• Language: English
• Published: England The British Institute of Radiology 01.09.2015
• Subjects: Animals; Biomarkers, Tumor - metabolism; Carcinoma, Renal Cell - drug therapy; Contrast Media; Diffusion Magnetic Resonance Imaging - methods; Disease Models, Animal; Feasibility Studies; Genitourinary Tract; Kidney Neoplasms - drug therapy; Magnetic Resonance Imaging - methods; Male; Mice; Mice, Nude; Niacinamide - analogs & derivatives; Niacinamide - therapeutic use; Phenylurea Compounds - therapeutic use; Prognosis; Protein Kinase Inhibitors - therapeutic use; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome
• DOI: 10.1259/bjr.20150163
• ISSN: 0007-1285

To investigate the feasibility of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DWI) in monitoring early therapeutic response to sorafenib in renal cell carcinoma (RCC) xenograft models. Sorafenib (40 mg kg(-1)) was administered orally to BALB/c nude mice (n = 9) bearing subcutaneous tumours of human RCC ACHN xenografts. DCE-MRI and DWI were obtained 0, 1, 3 and 7 days after therapy, and DCE-MRI parameters (K(trans) and ve) and apparent diffusion coefficient (ADC) values were calculated. Tumour size and volume changes were correlated with changes in DCE-MRI parameters or ADC values after therapy. Following therapy, K(trans) showed a significant decrease over time (p = 0.005), whereas ve did not demonstrate significant changes between time points (p = 0.97). ADC values showed a progressive increase over time (p = 0.004). Compared with pre-therapy, K(trans) showed a significant decrease after 3 days of therapy (p = 0.039), and ADC values increased significantly after 7 days (p = 0.039). Tumour size and volume did not show significant changes during 7 days. Tumour size and volume changes were not associated with changes in DCE-MRI parameters or ADC values. DCE-MRI and DWI may show early physiological changes within 1 week after initiating sorafenib treatment on human RCC xenografts. The quantitative parameters of DCE-MRI and DWI may offer the potential for assessing early therapeutic response to sorafenib in clinical trials.